Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

CorriXR Therapeutics

Company Type: Therapeutics

Main focus: Highly selective CRISPR-Cas therapies for cancer

Company stage: Pre-clinical

Diseases: Solid tumours

Genome-editing tool: CRISPR-Cas

Funding stage: Seed Funding

Location: Newark, Delaware, USA

Website: https://www.corrixr.com/

Pipeline:

Partners:

CorriXR Therapeutics is a pre-clinical-stage therapeutics company that leverages CRISPR-Cas to specifically hit cancer cells - sparing healthy cells - by targeting cancer-specific mutations in a selected target. CorriXR's current lead target is the NRF2 gene.

Tags

HashtagCorrixr Therapeutics

Company: CorriXR Therapeutics
close
Search CRISPR Medicine